Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
120,138,422
-
Number of holders
-
100
-
Total 13F shares, excl. options
-
45,474,760
-
Shares change
-
-1,378,605
-
Total reported value, excl. options
-
$1,240,848,739
-
Value change
-
-$38,040,013
-
Put/Call ratio
-
23%
-
Number of buys
-
60
-
Number of sells
-
-39
-
Price
-
$27.29
Significant Holders of Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) as of Q2 2021
120 filings reported holding ARQT - Arcutis Biotherapeutics, Inc. - Common Stock as of Q2 2021.
Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) has 100 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 45,474,760 shares
of 120,138,422 outstanding shares and own 37.85% of the company stock.
Largest 10 shareholders include FRAZIER MANAGEMENT LLC (8,434,232 shares), FMR LLC (7,530,736 shares), ORBIMED ADVISORS LLC (6,073,850 shares), BlackRock Inc. (4,248,620 shares), Bain Capital Life Sciences Investors, LLC (3,979,292 shares), Polar Capital Holdings Plc (1,682,543 shares), VANGUARD GROUP INC (1,494,276 shares), STATE STREET CORP (1,152,482 shares), PRICE T ROWE ASSOCIATES INC /MD/ (924,958 shares), and WELLS FARGO & COMPANY/MN (897,972 shares).
This table shows the top 100 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.